Palisade Bio, Inc. (PALI) vs Rocket Pharmaceuticals, Inc. (RCKT)
A side-by-side comparison of Palisade Bio, Inc. and Rocket Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PALI
Palisade Bio, Inc.
$1.50HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
RCKT
Rocket Pharmaceuticals, Inc.
$2.48HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — PALI vs RCKT
growth of $100 · dividends reinvested · last 10yPALI -100.0% (-71.2%/yr)RCKT -92.9% (-23.3%/yr)RCKT compounded faster over this window
Log scale — wide-divergence pair
PALI RCKT
PALI vs RCKT: by the numbers
- •RCKT is the larger company ($271M vs $260M market cap).
- •Both run net losses; RCKT's is the smaller (0.00% vs -6388.20% net margin).
Metrics side by side
Valuation
| Metric | PALI | RCKT |
|---|---|---|
| P/S ratio | 519.00 | N/A |
| P/B ratio | 2.13 | 0.74 |
Profitability
| Metric | PALI | RCKT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | -6388.20% | 0.00% |
| ROE | -26.24% | -4.68% |
| ROIC | -28.96% | -48.92% |
Growth (annualized)
| Metric | PALI | RCKT |
|---|---|---|
| Total return CAGR (5Y) | -76.02% | -38.33% |
Frequently asked
- How have PALI and RCKT total returns compared?
- Over the past 10 years, PALI delivered -71.24% and RCKT delivered -23.48% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.